Skip to Content

Baxter International Inc BAX

Morningstar Rating
$33.78 +0.04 (0.12%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Easing Pressures Should Boost Baxter's Prospects, Especially in 2025 and Beyond

Although the 2015 Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. We see these external pressures easing. Also, we suspect Baxter's financial prospects will improve, especially in 2025 and beyond, as hospitals renegotiate their reimbursement deals with third-party payers, and as Baxter renegotiates significant contracts, a key group purchasing organization among them.

Price vs Fair Value

BAX is trading at a 643% premium.
Price
$33.78
Fair Value
$65.00
Uncertainty
High
1-Star Price
$716.44
5-Star Price
$53.20
Economic Moat
Lskvl
Capital Allocation
Jdhjblyfm

Bulls Say, Bears Say

Bulls

In the long run, Baxter should continue to grow at a decent clip, primarily around evolutionary innovation in all of the major business lines and moderate pricing or mix improvements.

Bears

Although Baxter's products are essential for medical care and patient health, many have similar alternatives, which can limit pricing power.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BAX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$33.74
Day Range
$33.4133.83
52-Week Range
$31.0150.21
Bid/Ask
$33.57 / $33.99
Market Cap
$17.21 Bil
Volume/Avg
4.1 Mil / 4.1 Mil

Key Statistics

Price/Earnings (Normalized)
12.24
Price/Sales
1.15
Dividend Yield (Trailing)
3.43%
Dividend Yield (Forward)
3.43%
Total Yield
3.43%

Company Profile

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Mid Value
Total Number of Employees
60,000

Competitors

Valuation

Metric
BAX
FRE
ICUI
Price/Earnings (Normalized)
12.246.8819.00
Price/Book Value
2.110.861.34
Price/Sales
1.150.611.22
Price/Cash Flow
12.0814.1810.07
Price/Earnings
BAX
FRE
ICUI

Financial Strength

Metric
BAX
FRE
ICUI
Quick Ratio
0.870.600.92
Current Ratio
1.481.352.61
Interest Coverage
0.822.85−0.05
Quick Ratio
BAX
FRE
ICUI

Profitability

Metric
BAX
FRE
ICUI
Return on Assets (Normalized)
5.12%2.43%3.32%
Return on Equity (Normalized)
20.26%7.80%6.94%
Return on Invested Capital (Normalized)
7.70%4.23%5.84%
Return on Assets
BAX
FRE
ICUI
See how this stock stacks up to its competitors with Morningstar Investor

Medical Instruments & Supplies Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
XnmqljrgFbrln$151.0 Bil
Becton Dickinson & Co
BDX
TvdzcvfbmHhfqhr$67.5 Bil
Alcon Inc
ALC
HljkjhmdwYlwqtbk$44.4 Bil
ResMed Inc
RMD
FtjsbqsnvpSzhsy$31.1 Bil
Coloplast A/S ADR
CLPBY
GhvbwvhfHdmq$27.6 Bil
West Pharmaceutical Services Inc
WST
GstdhbydhLrsnj$24.4 Bil
The Cooper Companies Inc
COO
BcpfwwkjhPzfqjw$18.6 Bil
Hologic Inc
HOLX
VbyjhlkJswhszz$16.8 Bil
Teleflex Inc
TFX
VlhbFwrm$9.8 Bil

Sponsor Center